Mixed Treatment Comparisons, Network Meta-Analysis (NMA)

Read More


Health Economics Modeling: Cost-Effectiveness, Budget Impact (HAS CEESP, CEPS)

Read More


Real Life Medico-Economic Studies (SNDS)

Read More


Open Data and Data science

Read More


Health economics and Statistics


Statésia is a research and consulting firm specialized in comparative effectiveness research and medico-economic analysis of health products, technologies and strategies (for HAS CT, HAS CEESP, CEPS submissions).

Our competitive advantage is founded on a strong collaborative action with the Applied Mathematics Research team of the University of Maine (EA 3263), for performing suitable modeling techniques.

This decision analysis is founded on:

1- Comparative Effectiveness Research, Indirect and Mixed Treatment Comparisons (MTC, NMA) : Positioning your innovative technology in the studied therapeutic area;

2- Interactive Health Economics Modeling: Assessing the cost-effectiveness, the cost-utility or the cost-benefit of your innovative health product or technology;

3- Interactive Budget Impact Analysis (IBIA) : Assessing the affordability of your innovative product.


FaLang translation system by Faboba


New publicationSalah Ghabri PhD1, Aymeric Binard MD2, Yves-Marie Pers MD3, Franck Maunoury PhD4, J. Jaime Caro MD,CM, FRCPC, FACP567. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. Value in Health DOI: https://doi.org/10.1016/j.jval.2019.12.003. Available online 13 February 2020.

1 Department of Economic and Public Health Evaluation, French National Authority for Health (HAS), Saint-Denis La Plaine, France 2 Department of Rheumatology, CHU de la Cavale-Blanche, Brest, France 3 Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, France 4 STATESIA, Le Mans, France 5 McGill University, Montreal, QC, Canada 6 London School of Economics, London, England, UK 7 Evidera, Boston, MA, USA .

New publicationGordon Goodall1, Mark Lamotte2, Mafalda Ramos2, Franck Maunoury3, Barbora Pejchalova1, Gérard de Pouvourville4 (2019). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients, Journal of Medical Economics, DOI: 10.1080/13696998.2018.1559600.

1 Edwards Lifesciences S.A., Route de l'Etraz 70, 1260 Nyon, Switzerland, 2 IQVIA Corporate village, Davos building, Da Vincilaan 7, 1930 Zaventem, Belgium, 3 STATESIA, 19 Boulevard Marie et Alexandre Oyon, 72100 Le Mans, France, 4 ESSEC Business School, Av. Bernard Hirsch, B.P. 50105, 95021 Cergy Pontoise Cedex, France


Publication Franck Maunoury1, Christian Farinetto1, Stéphane Ruckly2, Jeremy Guenezan3, Jean-Christophe Lucet4, Alain Lepape5, Julien Pascal6, Bertrand Souweine7, Olivier Mimoz3, Jean-François Timsit8(2018) Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France. PLoS ONE 13(5): e0197747. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197747

1 Statesia, Le Mans, France, 2 ICURE Search, Outcomerea, Paris, France, 3 University Hospital of Poitiers, Emergency Department and Pre-Hospital Care, Poitiers, France, 4 Infection Control Unit, AP-HP, Bichat, University Hospital, Paris, France, 5 Department of Anaesthesiology and Critical Care Medicine, University, Hospital of Lyon-Sud, Lyon, France, 6 Adults Intensive Care Unit, Ongoing Monitoring Unit, Clermont, Ferrand University Hospital, Clermont-Ferrand, France, 7 Intensive Care Unit, Clermont Ferrand University, Hospital, Clermont-Ferrand, France, 8 Paris Diderot University - Bichat University hospital - Medical and Infectious Diseases Intensive care unit, Paris, France

Publication Maunoury F1, Clément A2, Nwankwo C3, Levy-Bachelot L2, Abergel A4, Di Martino V5, Thervet E6,7, Durand-Zaleski I8. (2018) Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. PLoS ONE 13(3). doi: 10.1371/journal.pone.0194329. eCollection 2018.

1 STATESIA, Le Mans, France, 2 MSD FRANCE, Paris, France, 3 Merck & Co., Inc., Kenilworth, New Jersey, United States of America, 4 Hepato-gastro enterology Service, CHU Estaing, Clermont-Ferrand, France, 5 Hepatology Department, Franche-Comté University and Besançon University hospital, Besançon, France, 6 HYPPARC Department, Nephrology Service, Paris Descartes University, Paris, France, 7 Georges Pompidou European Hospital (ET), Paris, France, 8 Ile-De-France URC ECO, Department of Public Health, Henri Mondor Hospital, Créteil, France

top arrow